So, wouldn't it be nice to have a quantitative way to say how deep the remission is? Historically, it’s been felt that if you just scratch the surface and get below the 5 percent blast level, you’re probably going to relapse. And if you get deeper, you might not.
The Food and Drug Administration (FDA) approved a supplemental new drug application that adds overall survival (OS) data from the phase 3 ENDEAVOR trial to the label for Kyprolis (carfilzomib) to treat patients with relapsed or refractory multiple myeloma.
A study, conducted at Penn State College of Medicine, demonstrated that patients with melanoma who received immunotherapy while also taking a specific type of beta blocker lived longer than those who received immunotherapy alone.
Many breast cancer survivors choose to adorn their chests with beautiful designs in an effort to camouflage unsightly scars. Could this practice be dangerous to their health? Read one survivor's viewpoint.
Philippa Cheetham, MD; Sara F. Martin, MD; and Evan C. Osmundson, MD, PhD, remark on recent improvements in managing advanced lung cancer, and offer insight regarding future therapies that show promise.
Philippa Cheetham, MD; Sara F. Martin, MD; Evan C. Osmundson, MD, PhD; and Leora Horn, MD, MSc, reflect on common challenges faced while treating advanced lung cancer and discuss their considerations for creating long-term treatment plans.
Susan Leclair, Ph.D., CLS (NCA), retired lab professor at University of Massachusetts, Dartmouth, discusses how moderating an online forum for patients with myeloproliferative neoplasms (MPNs) has inspired her.